Metabolic liver disease has long been understood as a systemic condition, but its reach into the esophagus has been poorly characterized — until now. A large-scale analysis suggests that adults with metabolic dysfunction-associated steatotic liver disease (MASLD) face dramatically elevated odds of developing both eosinophilic esophagitis and the full spectrum of gastroesophageal reflux phenotypes, raising questions about shared inflammatory pathways that conventional gastroenterology has yet to integrate into standard care protocols.
Using the TriNetX US Collaborative Network — one of the largest real-world clinical databases available — researchers conducted propensity score-matched comparisons across three distinct age cohorts totaling over 800,000 patients. Among adults aged 18–44, MASLD was associated with nearly threefold greater odds of eosinophilic esophagitis (OR = 2.905). This association remained robust and statistically significant in middle-aged (OR = 2.423) and older adults (OR = 2.327), suggesting a persistent biological link rather than an age-confounded artifact. Elevated odds for erosive esophagitis, nonerosive reflux disease, and Barrett's esophagus were also observed across all strata.
These findings deserve careful contextual framing. MASLD and both esophageal conditions share overlapping metabolic risk factors — central adiposity, insulin resistance, and systemic low-grade inflammation — making directionality difficult to establish in any observational design. Propensity score matching adjusts for measured confounders but cannot eliminate unmeasured ones, such as dietary pattern quality or microbiome composition, which may independently drive both hepatic steatosis and esophageal inflammation. The EoE association is particularly striking because EoE is traditionally framed as an atopic, immune-mediated condition; finding it clustered with a metabolic liver phenotype challenges the dominant allergic paradigm and points toward adipose-driven cytokine signaling — particularly IL-5 and eotaxin pathways — as a plausible mechanism worthy of prospective investigation. Clinically, this work is incrementally significant: it does not establish causation, but it does make a compelling population-level case for esophageal surveillance in MASLD patients beyond standard hepatic monitoring.